1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

Sponsor
Unidad Integral de Investigación en Oncología S.L.
Study ID
NCT00345696
Phase
PHASE2
Status
Completed

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
  • Capecitabine — DRUG
    600 mg/m2, orally, every 12 hours, continuous.
  • Oxaliplatine — DRUG
    85 mg/m2, intravenous, 2 hours infusion, every 2 weeks

Study Details

The purpose of this study is to determinate progression free survival after 9 months of treatment.

Key Dates

First listed
Jun 28, 2006
Start date
Jun 30, 2006
Status verified
Aug 2011
Primary completion
Oct 31, 2008
Completion
Jan 31, 2011

Study Design

Enrollment
32 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Progression Free Survival [ Time Frame: 9 months ]

Related Studies